Tenon Medical, Inc. Q1 FY2026 earnings call

• Financial Performance

  • Q1 2026 revenue and gross profit are the highest of any first quarter in company history, with 90% year-over-year revenue growth and 24 percentage points of gross margin expansion.
  • Gross margin expansion is driven by improved absorption of fixed production overhead from higher revenue, a streamlined commercial footprint, and stronger field productivity; management expects these structural margin gains to persist.
  • Operating expenses were $4.2 million, a modest increase from $4.0 million in prior year Q1, driven by higher sales and marketing for the Symmetry Plus rollout and increased R&D for upcoming product launches, partially offset by lower stock-based compensation.
  • Net loss narrowed to $3.5 million ($0.31 per diluted share) from $3.6 million ($1.01 per diluted share) in the prior year Q1.
  • The company closed a $4.3 million senior convertible note placement in March 2026, ending the quarter with $4.6 million in cash and cash equivalents, extending operating runway and providing flexibility for strategic investments.

• Product and Pipeline Progress

  • The two-platform portfolio of Catamaran (inferior posterior approach) and Symmetry Plus (lateral/oblique approach) is gaining adoption as complementary tools for primary and revision sacral pelvic procedures at leading medical centers.
  • 21 physicians were trained on both systems during the quarter. A new, dedicated training and education center has been opened in Tampa, Florida to accelerate physician and distributor training, and an experienced senior sales leader was added to manage the eastern U.S. region.
  • R&D activity has accelerated: significant product enhancements for Symmetry Plus are on track for launch in the second half of 2026, and regulatory submission and alpha testing for a third sacral pelvic approach product are planned for Q4 2026.

• Intellectual Property

  • The U.S. Patent and Trademark Office issued multiple notices of allowance for patent applications expected to grant in 2026, building on 10 patents granted in 2025. The company's current portfolio includes 29 granted U.S. patents, 9 granted international patents, and 31 pending applications, providing protection for Catamaran and Symmetry Plus.

Tenon Medical operates two product segments, Catamaran and Symmetry Plus. Total company Q1 2026 revenue was $1.4 million, a 90% increase from $0.7 million in the prior year Q1. Catamaran delivered strong year-over-year procedure volume growth driven by new physician adoption, contributing the majority of total revenue. Symmetry Plus, acquired in August 2025, contributed its first full quarter of revenue in Q1 2026, accounting for a meaningful portion of the period's total revenue growth. Total Q1 2026 gross profit was $0.9 million (68.5% gross margin), a 193% increase from $0.3 million (44.5% gross margin) in the prior year Q1.

• Management expects gross margin to remain in the high 60% range for the remainder of 2026, and to expand to 70% or higher as revenue scales in 2027 and beyond, as fixed production overhead is further absorbed.
• Operating expenses are expected to increase modestly from the Q1 2026 baseline through the rest of 2026, but revenue will grow at a faster rate than operating expenses, supporting expanding profitability.
• Full commercial launch of enhanced Symmetry Plus components is on track for the second half of 2026, with a full commercial launch of the new third approach product planned for Q1 2027 following Q4 2026 alpha testing.
• Management confirms that 2026 core priorities are growing procedure volumes across both platforms, expanding the trained physician base, and maintaining cost discipline to sustain the newly achieved gross margin gains.

• All forward-looking statements regarding product launch timelines, future revenue growth, and margin expansion are subject to inherent risks and uncertainties that could cause actual results to differ materially from current expectations, including regulatory and clinical development risks, hospital approval and access challenges, and adoption hurdles for new medical technologies.
• A key organizational challenge is streamlining and accelerating hospital committee approval and access processes, which are required to convert trained interested physicians into consistent users of the company's products.

Q: Given typical Q1 seasonality headwinds from deductible resets that depress elective surgical procedure volumes, is the strong Q1 2026 result as encouraging as it appears? / A: Steve Foster confirmed that the seasonality dynamic described is accurate for Tenon, as it is for other elective medical device companies. Despite these typical Q1 headwinds, the quarter delivered solid, strong results that the company views as encouraging and a good start to 2026. This outperformance against seasonal headwinds reinforces the strength of the company's current growth trajectory.

Q: How should investors think about OPEX for the rest of 2026 – is Q1 2026 OPEX a good baseline? / A: Kevin Williamson confirmed that Q1 2026 OPEX is a good fixed cost baseline for the full year. The company will make incremental investments through the year that will lead to a modest OPEX increase, but OPEX will grow at a slower rate than revenue, allowing continued operating leverage and improving profitability as the year progresses. The company has maintained cost discipline to lay growth foundation without overexpanding fixed costs.

Q: How does the upcoming Q4 2026 alpha third approach product differ from the existing two platforms, and what is the commercialization timeline? / A: Steve Foster explained that the new product follows Tenon's core fusion and arthrodesis-focused design principles, which the company views as a key differentiator in the market, while adding a new surgical approach preferred by many physicians. After Q4 2026 alpha testing with early physician advisors to refine the product, a full commercial launch is planned for Q1 2027, matching the timeline that analyst Anthony Vendetti hypothesized.

Q: Gross margin hit 68.5% in Q1 – is this level sustainable for the rest of 2026, and what is the long-term margin target? / A: Kevin Williamson confirmed that high 60% gross margin is a good baseline for the remainder of 2026. As revenue scales further, the company will continue to absorb fixed logistics and production costs, so gross margin is expected to expand over the coming quarters, reaching 70% or higher in 2027 and beyond, matching the market expectation.